Details for Patent: 7,780,984
✉ Email this page to a colleague
Title: | Methods and compositions for treating proliferative diseases |
Abstract: | The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. |
Inventor(s): | Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA), De; Tapas K. (Los Angeles, CA) |
Assignee: | Abraxis Bioscience, LLC (Los Angeles, CA) |
Filing Date: | Jul 20, 2007 |
Application Number: | 11/880,314 |
Claims: | 1. A method of treating a cancer disease in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising 17-AAG and an albumin, wherein the nanoparticles comprise 17-AAG coated with the albumin. 2. The method according to claim 1, wherein the cancer is lung cancer. 3. The method according to claim 1, wherein the 17-AAG is administered intravenously. 4. The method according to claim 1, wherein the albumin is human serum albumin. 5. The method according to claim 1, wherein the average diameter of the nanoparticles in the composition is no greater than 200 nm. 6. The method according to claim 1, wherein the weight ratio of the albumin to 17-AAG in the composition is less than 18:1. 7. The method according to claim 4, wherein the average diameter of the nanoparticles in the composition is no greater than 200 nm. 8. The method according to claim 7, wherein the weight ratio of the albumin to 17-AAG in the composition is less than 18:1. 9. The method according to claim 1, wherein the composition does not induce significant side effects. 10. The method according to claim 5, wherein the average diameter of the nanoparticles in the composition is no greater than 100 nm. 11. The method according to claim 6, wherein the weight ratio of the albumin to 17-AAG in the composition is about 3:1 to about 12:1. |